Biogen’s big blow on its top seller

Biogen’s big seller drug Adulhem has been retired from Medicare and Medicaid after failing to prove a real benefit to the patients suffering from Alzheimer’s disease. Is this going to affect the market value of Biogen? What is next in the Alzheimer’s medication?

Read More